Article
Growth hormone (GH) dose, but not exon 3-deleted/full-length GH receptor polymorphism genotypes, influences growth response to two-year GH Therapy in Short Small-for-Gestational-Age Children.
The Journal of clinical endocrinology and metabolism - 1 Jan 2008
Carrascosa Antonio, Audí Laura, Esteban Cristina, Fernández-Cancio Mónica, Andaluz Pilar, Gussinyé Miquel, Clemente María, Yeste Diego, Albisu María Angeles
Abstract excerpt
CONTEXT: In short small-for-gestational-age (SGA) patients, the exon 3-deleted(d3)/full-length (fl)-GHR polymorphism was associated with responsiveness to GH therapy (30-48 microg/kg.d); however, these results were not confirmed for higher GH doses (56-66 microg/kg.d). We hypothesized that higher doses would mask the lower dose differences. OBJECTIVE: Our objective was to evaluate, in short SGA patients, 2-yr...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.